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AutoimmunityNo disease-speciﬁc neuronal antibodies have so far been deﬁned in neuro-Behçet's disease (NBD). Immuno-
histochemistry and immunocytochemistry studies showed antibodies to hippocampal and cerebellar molec-
ular layers and the surface antigens of cultured hippocampal neurons in sera and/or cerebrospinal ﬂuids
(CSF) of 13 of 20 NBD and 6 of 20 BD patients but not in multiple sclerosis or headache controls. Screening
with a protein macroarray led to identiﬁcation of stress-induced-phosphoprotein-1 (STIP-1) as an antigenic
target. High-titer STIP-1-antibodies were detected in 6 NBD patients' sera but not in controls. These results
suggest that neuronal antibodies could be useful as diagnostic biomarkers in NBD., Istanbul University, Istanbul
l.: +90 212 4142000x32580;
rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Behçet's disease (BD) is a chronic, recurrent and inﬂammatory dis-
order characterized with oral and genital aphthous ulcerations, uve-
itis, skin lesions and skin pathergy reaction. Several tissues such as
blood vessels, eyes, skin, joints, lungs and brainmay be affected during
the course of this disease. The involved tissues generally show a non-
speciﬁc mononuclear and neutrophilic inﬂammatory reaction (Gül,
2005; Yurdakul and Yazici, 2008). Although the etiology of BD remains
unknown, the presence of inﬂammatory lesions and identiﬁcation of
antibodies directed against antigens shared between microorganisms
and the involved tissues of the patients [e.g. heat shock proteins
(HSPs)] have suggested an autoimmune nature (Lehner et al., 1991)
but efforts to demonstrate autoantibodies that are highly sensitive
and speciﬁc to BD have so far failed.
The central nervous system (CNS) involvement, named as neuro-
Behçet's disease (NBD), develops in 5–10% of BD patients andgenerally afﬂicts the brain parenchyma and less frequently the brain
vessels and meninges (Akman-Demir et al., 1999). In an attempt to
identify disease and tissue speciﬁc (i.e. anti-neuronal) antibodies,
serum and cerebrospinal ﬂuid (CSF) samples of NBD patients and
controls were screened using immunohistochemistry, immunocyto-
chemistry and protein macroarray and the results were compared
with demographic and clinical features of the patients.
2. Materials and methods
2.1. Patients and samples
Twenty consecutive NBD patients (9 women, 11 men; mean age±
standard deviation, 43.6±12.1), who were followed in our outpatient
clinic and whose serum and CSF samples were available were included.
The average NBD duration of these patients was 9.1±5.1 years. Con-
trols included twenty age- and gender-matched BD patients with pri-
mary headache disorders without neurological involvement (BD), (10
women, 10 men; mean age±standard deviation, 43.1±10.4), 20
with multiple sclerosis (MS) (11 women, 9 men; mean age±standard
deviation, 41.9±11.7) and 20 with primary headache disorders only
(10 women, 10 men; mean age±standard deviation, 42.5±9.2).
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than BD or MS.
All NBD and BD patients fulﬁlled the diagnostic criteria for BD
(International Study Group for Behçet's Disease, 1990) and all MS pa-
tients fulﬁlled the McDonald's criteria for deﬁnite MS (Polman et al.,
2005). Thirteen of the NBD patients had parenchymal lesions in the
brain (parenchymal NBD) and 7 NBD patients had dural sinus thrombo-
sis (vascular NBD). All NBD and BD patients underwent a pathergy test
and a positive result was obtained in 14 and 16 of NBD and BD patients,
respectively. The Expanded Disability Status Scale (EDSS) scores of
NBD patients were calculated during serum and CSF sampling.
An informed consent was obtained from all participants before
the blood and CSF samples were obtained. Sera were kept frozen at
−80 °C until assayed. All CSF samples were tested for protein, glucose
and cell content and for the presence of oligoclonal bands. Serum and
CSF samples of NBD and MS patients were obtained as a part of routine
diagnostic work-up, whereas those of BD and headache patients were
obtained during the diagnostic work-up of severe headache. BD pa-
tients andheadache controls had noother neurological complaints, nor-
mal neurological examination, normal CSF protein, glucose and cell
content and no abnormal ﬁndings or lesions in cranial magnetic reso-
nance imaging (MRI). CSF sampling had been done during a neurologi-
cal attack in 15 NBD patients. The study was approved by the Ethics
Committee of Istanbul Faculty of Medicine of Istanbul University.
2.2. Immunohistochemistry on rat brain sections
Whole rat brain was treated ﬁrst with 4% paraformaldehyde over-
night at 4 °C, immersed in 40% sucrose overnight at 4 °C andFig. 1. Immunolabeling of frozen rat brain sections and cultured live hippocampal cells with
patient shows intense reactivity with the cytoplasms of Purkinje cells and cerebellar molecu
the area of the cerebellum included in the box (B) shows no immunoreactivity with the CSF
pocampal neurons (D–F) using a NBD patient's serum sample (D, green) and an antibody to
of reactivities (E) (original magniﬁcation for panels A–C is ×100 and for Panel D–F is ×400)
with hematoxylin counterstaining.subsequently snap frozen in liquid nitrogen. Seven micrometer-thick
frozen sections were serially incubated with 0.3% H2O2 for 20 min,
10% goat serum for 1 h and serum/CSF samples (1:200 and 1:2, respec-
tively) overnight at 4 °C. They were then incubated in biotinylated
goat anti-human IgG (1:2000, Vector Laboratories, Burlingame, CA),
and the immunoreactivity developed by serial incubation with avi-
din–biotin peroxidase (Vector Laboratories) for 1 h and diaminoben-
zidine (Irani et al., 2010a). The immunohistochemistry results were
assessed by two independent observers (E.T. and S.İ.), who were
blind to patients' identities. Moderate to strong diaminobenzidine-
induced brown color that could be localized to a discrete anatomical
and/or subcellular location (e.g. cytoplasm, nucleus, cerebellar molec-
ular layer etc.) was considered as anti-neuronal antibody positivity
(Fig. 1A,B). The absence (Fig. 1C) or very weak presence of brown
staining that cannot be robustly distinguished from non-speciﬁc back-
ground staining was accepted as negative. The IgG binding patterns
were classiﬁed as neuronal nuclear, cytoplasmic and neuropil (immu-
nolabeling of the neuronal axons and dendrites located in cerebellar
and/or hippocampal molecular layers) staining.
2.3. Immunoﬂuorescence on live neurons
Antibodies to neuronal surface antigens were detected as described
previously (Irani et al., 2010a). Primary cultures of hippocampal neu-
rons were prepared from P1 rat pups that were killed by decapitation.
Hippocampi were isolated from the brain and collected in chilled
HBSS (Hanks' Balanced Salt Solution), with antibiotic–antimytotic, and
incubated in 1% trypsin-EDTA solution at 37 °C for 30 min. The solution
was aspirated and the hippocampi triturated using a 1 ml and 200 μlthe cerebrospinal ﬂuid (CSF) of neuro-Behçet's disease (NBD) patients. CSF IgG of a NBD
lar layer (A). In an adjacent brain section, cerebellar molecular layer corresponding to
sample of a multiple sclerosis patient (C). Double immunolabeling of cultured rat hip-
the neuronal marker microtubule-associated protein 2 (F, red); note the co-localization
. Staining for panels A–C was performed with the avidin–biotin–peroxidase technique
Fig. 2. Silver-stained 10% SDS-PAGE analysis of puriﬁcation of stress-induced-
phosphoprotein 1 (STIP-1), heat-shock protein 70 (Hsp-70), stathmin-like 4
(STMN4) and inhibitor of growth family, member 4 (ING4). Molecular masses of puri-
ﬁed proteins STIP-1, Hsp-70, STMN4 and ING4 were found to be about 63, 70, 22 and
29 kDa respectively, consistent with the predicted values.
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10% fetal calf serumandpenicillin/streptomycin. After low speed centri-
fugation (1000 rpm, 4 min) the supernatant was discarded and the
cells were resuspended in complete MEM and plated onto 13 mm di-
ameter glass coverslips coated with poly-L-lysine in 6-well plates. Cul-
tures were grown at 37 °C in a humidiﬁed 95% O2 5% CO2 atmosphere.
Twenty four hours after plating, and then twice weekly, half of the me-
dium was replaced with neurobasal culture medium with added
glutamine, antibiotic–antimytotic and B27 (Invitrogen, UK). For immu-
noﬂuorescence experiments, after at least 7 days in vitro, the coverslips
were transferred into 24-well plates and incubated with patients' sera
diluted 1:250 in 1%BSA-Hepes-Neurobasal for 1 h at room temperature,
followed by ﬁxation (3% formaldehyde for 15 min) and by incubation
with Alexa Fluor 488 conjugated anti-human IgG (Invitrogen, UK) for
45 min. Subsequently the cells were permeabilized with 0.3% PBST
(0.3% Triton X-100 in PBS) for 15 min at room temperature and incubat-
ed with mouse monoclonal microtubule-associated protein 2 (MAP2)
antibody (Sigma-Aldrich, UK) (a marker of axonal and dendritic pro-
cesses) diluted 1:1000 in 1% BSA for 1 h at room temperature, followed
by incubationwith Alexa Fluor 568 conjugated anti-mouse IgG (Invitro-
gen, UK) at 1:1000 dilution for 45 min. Cells were mounted and
images were photographed under a Zeiss ﬂuorescence microscope
with a digital camera using the Zeiss Axiovision software. The immuno-
ﬂuorescence results were assessed by two independent observers (E.T.
and E.E.), who were blind to patients' identities. Moderate to strong
Alexa Fluor 488-conjugated anti-human IgG-induced green color that
colocalized with Alexa Fluor 568-conjugated anti-mouse IgG-induced
red color (Fig. 1D–F) was considered as positive.
2.4. Autoantibodies to ion channels
Serum antibodies to voltage-gated potassium channel (VGKC)-
complex autoantigens were measured by radioimmunoassay using
whole rat brain homogenate and 125I-dendrotoxin, as described pre-
viously (Vincent et al., 2004; Majoie et al., 2006; Irani et al., 2010b).
For N-methyl-D-aspartate receptor (NMDAR) antibody detection,
human embryonic kidney (HEK293) cells were grown on glass
coverslips in Dulbecco's modiﬁed Eagle's medium with 10% fetal
calf serum and penicillin, streptomycin and amphotericin. After
24 h, cells were transfected, using polyethylenimine and glucose,
with untagged-NR1 and NR2B cDNA at a ratio of 3:1. An EGFP ex-
pression vector was co-transfected to visualize cells taking-up
cDNAs. To prevent cytotoxicity as a result of glutamate in the medi-
um activating the NMDARs, cells were supplemented with 500 μM
ketamine 16 h post-transfection. Transfected cells were then incu-
bated with patients' serum (1:400) for 1 h followed by 30 min incu-
bation with Alexa Fluor 568 anti-human IgG. Cells were
subsequently washed three times in phosphate buffered saline and
mounted on slides in ﬂuorescent mounting medium (DakoCytoma-
tion, Cambridge, UK) containing DAPI (4′,6′-diamidino-2-phenylin-
doledichloride, 1:1000). They were visualized with a Zeiss
ﬂuorescence microscope with a digital camera using the Zeiss Axio-
vision software (Irani et al., 2010a).
2.5. Proteinmacroarray, sequencing of cDNA inserts and protein expression
Sera of NBD patients were screened by using a high-density protein
macroarray derived from human fetal brain cDNA expression library
(hEX1),which contains approximately 24,000 clones (ImaGenes, Berlin,
Germany). To identify the target antigens of the anti-neuronal anti-
bodies, hEX1 arrays were prepared and incubated with pooled serum
samples of 4 NBD patients with the strongest anti-neuronal antibody
staining obtained by immunohistochemistry and immunoﬂuorescence
studies, as described previously (Büssow et al., 1998; Preuss et al.,
2009). Images were captured and analyzed for signal intensity (Visual-
Grid, GPC Biotech, Martinsried, Germany). The arrays were scoredbetween 0 (absent), 1 (weak) and 3 (strong) conﬁrmed bymatched du-
plicates. Selected expression cloneswere obtained (ImaGenes). Plasmid
DNA fromcloneswas isolated for DNA sequencing (Qiagen, Hilden, Ger-
many) according to the manufacturer's instructions. Cloned cDNAs in
the puriﬁed plasmid DNA were sequenced by Iontek Laboratory (Istan-
bul, Turkey). Nucleotide and translated amino acid sequences were
compared with known sequences using BLAST algorithms (National
Center for Biotechnology Information, Bethesda, MD). Following the
conﬁrmation of the selected clones, His-tagged proteins were recombi-
nantly expressed in E. coli, puriﬁed by afﬁnity chromatography and the
purity of the proteinswas documented by SDS-PAGE analysis (Fig. 2), as
reported previously (Preuss et al., 2009).2.6. Enzyme-linked immunosorbent assay
Detection of antibodies to the puriﬁed recombinant human proteins
in the sera and CSF of study subjects was performed with an enzyme-
linked immunosorbent assay (ELISA). The puriﬁed proteins (50 μl at
10 μg/ml) were added to the wells of a 96-well high-binding-capacity
plate and incubated overnight at 4 °C. Wells coated with the E. coli ly-
sate or only with bovine serum albumin were used as controls. The
plates were washed with Tris-buffered saline (TBS) containing 0.1%
Tween 20 (TBS-T) and blocked for 2 h with 5% skim milk in TBS. A
60 μl aliquot of each serum (diluted 1:100) and CSF (undiluted) sample
in TBS-T was added to protein coated wells and incubated for 2 h at
room temperature. The plates were washed six times with TBS-T fol-
lowed by the addition of 60 μl of alkaline phosphatase (AP)-conjugated
goat anti-human IgG (Southern Biotech, Birmingham, AL, USA) diluted
1:2000 in TBS-T and then incubated at room temperature for 1 h.
After washing, 60 μl of 2-(2-benzothiazoyl)-6-hydroxybenzothiazole
phosphate (BBTP) was added for 45 min at room temperature followed
by addition of the stopping solution (3 N NaOH). Fluorescent signals
weremeasured at 450/50 excitation and 580/50 emissionwith amicro-
plate reader. For each sample, the value obtained from the protein-
coated well was subtracted from the non-coated well. The obtained re-
sults were expressed as signal ratios (sample signal/mean signal of the
headache controls). Positivity was deﬁned as 2 standard deviations
above the mean of headache controls.
Table 1
Distribution of immunohistochemistry (IHC) staining patterns and anti-neuronal antibodies among patient groups.
IHC staining patterns with serum samples IHC staining patterns with CSF samples Serum antibodies against
Neuropil Nucleus Cytoplasm Neuropil Nucleus Cytoplasm Neurons VGKC NMDAR
NBD (n=20) 13 1 0 7 1 0 10 1 0
BD (n=20) 6 0 1 1 0 1 5 0 0
MS (n=20) 0 2 0 0 0 0 0 0 0
HC (n=20) 0 1 0 0 0 0 0 0 0
CSF, cerebrospinal ﬂuid; neuropil, staining of axon terminals and dendritic projections located in cerebellar and/or hippocampal molecular layers; neurons, antibodies reacting with
axonal and dendritic projections of cultured rat hippocampal neurons detected by immunocytochemistry; VGKC, voltage-gated potassium channel; NMDAR, N-methyl-D-aspartate
receptor; NBD, neuro-Behçet's disease; BD, Behçet's disease patients with no neurological involvement; MS, multiple sclerosis; HC, headache controls.
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The puriﬁed STIP-1 protein was denatured (100 °C, 5 min), 1 μg
puriﬁed protein was loaded in each lane, electrophoresed (10% acryl-
amide gel) and transferred to 0.45-μm polyvinylidene ﬂuoride mem-
branes (100 V, 80 min). Membranes were blocked (5% milk in TBS-T;
90 min) and incubated with individual human sera (diluted 1:2000)
or rabbit anti-human stress-induced-phosphoprotein 1 (STIP-1,
1:200 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA) followed
by HRP-conjugated goat anti-human IgG or goat anti-rabbit IgG (Jack-
son ImmunoResearch Laboratory) at 1:1000 dilutions. Immunoreac-
tivity was visualized on chemiluminescent ﬁlm using ECL Western
blotting substrate (Pierce, Thermo Scientiﬁc, USA) according to the
manufacturer's instructions.
2.8. Statistics
The demographic and clinical features of NBD patients were com-
pared using chi-square, Student's t or Mann–Whitney U tests, as appro-
priate. Signal ratios obtained in ELISA experiments were compared
among groups by ANOVA. A p value smaller than 0.05 was considered
to be statistically signiﬁcant.
3. Results
3.1. Anti-neuronal antibodies in NBD and BD patients
Immunohistochemistry studies revealed serum and/or CSF IgGs
immunoreacting with the neuronal nucleus, cytoplasm or neuropil
antigens in 14 NBD (70%) and 7 (35%) BD patients (p=0.01 by chi-Table 2
Comparison of clinical and demographic features of neuro-Behçet's disease (NBD) patients
Neuronal-Ab negative
(n=6)
Gender (women/men) 3/3
Age (mean±SD) 45±12.7
Patients with a positive pathergy test 4
Patients with samples obtained during an attack 3
EDSS during sampling (mean±SD) 5.8±1.5
Patients with relapsing remitting/progressive clinical course 4/2
Patients with parenchymal/vascular NBD 5/1
Duration of BD during sampling (years; mean±SD) 18±6.9
Duration of NBD during sampling (years; mean±SD) 10±7.6
Patients with high (N5/mm3) CSF cell count during sampling 3
Patients with high CSF protein (N45 mg/dl) during sampling 5
Patients with CSF oligoclonal bands during sampling 1
Patients with serum/CSF neuropil antibodies NA
Ab, antibody; SD, standard deviation; EDSS, The Expanded Disability Status Scale; CSF, cere
a Chi-square test.
b Student's t-test.
c Mann–Whitney U test.square test). The IgGs primarily reacted with the neuropil antigens
in 13 (65%) NBD and 6 (30%) BD patients (p=0.01 by chi-square
test), whereas one NBD patient and one BD patient had serum and
CSF antibodies against neuronal nuclear or cytoplasmic antigens, re-
spectively. Anti-neuropil antibodies were detected only in the sera
of 6 NBD and 5 BD patients and in both serum and CSF samples of 7
NBD patients and 1 BD patient. None of the NBD or BD patients had
neuropil antibodies in the CSF only. While no neuropil antibodies
were detected in the sera or CSF of MS and headache patients, anti-
neuronal nuclear antibodies were identiﬁed in the sera of 1 headache
and 2 MS patients (Fig. 1A–C, Table 1). The diffuse molecular layer
staining obtained with NBD patients' serum and CSF IgGs was remi-
niscent of those previously obtained with ion-channel antibodies
(Ances et al., 2005; Lancaster et al., 2010).
Antibodies to neuronal surface antigens of the cultured hippocam-
pal neurons were identiﬁed in the sera of 10 (50%) NBD but only 5
(25%) BD patients (p=0.05 by chi square test) and not in those of
MS and headache patients (Fig. 1D, Table 1). All positive samples
had also shown neuropil staining by immunohistochemistry. More-
over, double immunolabeling of hippocampal neuronal cultures
with NBD and BD patients' serum antibodies and MAP-2 antibody (a
marker of neuronal axonal and dendritic processes) showed co-
localization (Fig. 1D–F), indicating that the staining identiﬁed was re-
lated to neuronal processes rather than glial cells and consistent with
the presence of neuropil antibodies.
Since neuropil antibodies have generally signiﬁed the presence of
antibodies directed against cell surface antigens, including various
ion-channels (Vincent et al., 2004; Irani et al., 2010a), we examined
serum antibodies against well-characterized neuronal surface auto-
antigens, the VGKC-complex autoantigens and NR1/NR2 subunits ofwith and without neuronal or stress-induced-phosphoprotein 1 (STIP-1) antibodies.
Neuronal-Ab positive
(n=14)
p value STIP-1 Ab negative
(n=14)
STIP-1 Ab positive
(n=6)
p value
6/8 0.38a 5/9 4/2 0.11a
43±12.2 0.42b 43.3±12.9 44.3±8.5 0.42b
10 0.41a 9 5 0.19a
12 0.04a 10 5 0.29a
5.2±1.6 0.39c 4.1±0.9 4.4±2.1 0.35c
12/2 0.16a 11/3 5/1 0.41a
8/6 0.14a 8/6 5/1 0.14a
14±9.8 0.18b 16.1±8.9 12.8±8.8 0.22b
8±3.6 0.25b 9.4±6.1 7.8±5.1 0.17b
9 0.27a 9 3 0.27a
10 0.29a 11 4 0.29a
3 0.41a 2 2 0.16a
NA NA 8 5 0.14a
brospinal ﬂuid; NA, not applicable.
Table 3
Frequencies of serum antibodies to antigens isolated by protein macroarray in patient and control groups.
Antigen Accession no. Number of clones NBD
(n=20)
BD
(n=20)
MS
(n=20)
HC
(n=20)
STIP-1 (stress-induced-phosphoprotein 1 or heat shock
protein 70/90-organizing protein)
NP_006810 1 6 0 0 0
HSP-70 (heat shock 70 kDa protein) NM_002154 1 2 3 7 0
STMN4 (stathmin-like 4) NM_030795 1 2 0 2 0
ING4 (inhibitor of growth family, member 4) NM_016162 1 1 2 5 0
NBD, neuro-Behçet's disease; BD, Behçet's disease patients with no neurological involvement; MS, multiple sclerosis; HC, headache controls; NA, not available.
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bodies to VGKC-complex autoantigens (396 pM) (Table 1).
NBD patients with and without neuronal antibodies did not signiﬁ-
cantly differ in terms of gender, age, neurological disability, clinical
course, disease duration and laboratory ﬁndings. However, a signiﬁ-
cantly higher antibody positivity ratewas observed in samples obtained
during a neurological attack (p=0.04, chi-square test) (Table 2).
3.2. Differential autoantibody expression between NBD and control
patients
To identify the target antigens of NBD-associated neuronal auto-
antibodies, we screened the sera of NBD patients by a protein macro-
array derived from a human fetal brain cDNA expression library.
This analysis identiﬁed four clones that had the highest signal inten-
sity (3) and number of duplicates (more than 2): STIP-1 (or HSP
70/90-organizing protein), heat shock 70 kDa protein (HSP-70),
stathmin-like 4 (STMN4) and inhibitor of growth family, member 4
(ING4). ELISA studies performed with the corresponding recombi-
nant proteins revealed high-titer autoantibodies in varying numbers
of NBD, BD and MS patients. MS patients displayed an increased fre-
quency of high-titer autoantibodies to HSP-70 (7 patients, 35%) and
ING4 (5 patients, 25%) than NBD and BD patients (0–3 patients, 0–
15%). Alternatively, high-titer STIP-1 autoantibodies were only
detected in the sera of NBD patients (6 patients, 30%) (Table 3,
Fig. 3). None of the patients' sera gave high-titer antibody values
with the lysate of the E. coli strain used to express the proteins, sup-
porting the speciﬁcity of the autoantibody measurements and sug-
gesting that the positivities were not due to crossreaction withFig. 3. ELISA detection of IgG antibodies directed against stress-induced-phosphoprotein 1 (
(ING4) (C), stathmin-like 4 (STMN4) (D), and the E. coli lysate (E) in sera of neuro-Behçet
(BD), multiple sclerosis patients (MS) and headache controls (HC). The dashed lines represe
ity). Horizontal lines indicate the mean value of each group. ***, pb0.001 by ANOVA.E. coli proteins (Fig. 3E). None of the CSF samples of NBD, BD, MS
and headache patients had detectable antibodies directed against
the tested recombinant proteins (data not shown). The binding to
STIP-1 was conﬁrmed by immunoblotting comparing with an anti-
body to STIP-1 (Santa Cruz Biotechnology). Both the commercial
and the positive NBD sera bound a band at 63 kDa (Fig. 4).
There were no signiﬁcant differences between the demographic
and clinical parameters of STIP-1 antibody positive and negative
NBD patients. Also, there was no evident association between the
presence of STIP-1 and neuropil antibodies (p=0.14 by chi-square
test) (Table 2).
4. Discussion
Although autoimmunity has often been considered in BD and NBD,
previous studies have not succeeded in identifying useful biomarkers
or potentially pathogenic autoantibodies. Here, we have shown that
there are autoantibodies to neuronal cell surface antigens in a propor-
tion of NBD patients, greater than in BD controls, and that there are
also antibodies to STIP-1.
Previously identiﬁed neuropil antibodies have been shown to
mostly react with the conformational epitopes of neuronal ion-
channels. The best examples are NMDAR and components of the
VGKC-complex (Vincent et al., 2004; Majoie et al., 2006; Irani et al.,
2010a; Irani et al., 2010b). Antibodies to these cell-surface proteins
are now being identiﬁed routinely in patients who have immunother-
apy responsive forms of limbic encephalitis and encephalopathy.
Unfortunately, screening of NBD patients' sera with a protein macro-
array failed to reveal the antigenic targets of these neuropilSTIP-1) (A), heat-shock protein 70 (Hsp70) (B), inhibitor of growth family, member 4
's disease (NBD) patients, Behçet's disease patients with no neurological involvement
nt 2 standard deviations above the mean of the HC samples (cut-off values for positiv-
Fig. 4. Representative immunoblots for Western blot analysis of recombinant stress-
induced-phosphoprotein 1 (STIP-1) protein. While both rabbit anti-human STIP-1 an-
tibody (Ab) (1) and neuro-Behçet's disease (NBD) patients' sera that were found to be
positive for STIP-1 Ab by ELISA (2) yielded ~63 kDa bands at the STIP-1 protein loaded
gels, NBD sera that were seronegative for STIP-1 Ab by ELISA (3) did not.
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sera were also positive for neuropil antibodies, STIP-1 antibody
could not be identiﬁed in 8 neuropil antibody positive sera
(Table 2). Nevertheless, considering that STIP-1 is not only conﬁned
to the cytoplasm but is also expressed at the cell surface (Zanata et
al., 2002), at least one of the antigenic targets of the neuropil anti-
bodies might be STIP-1. Given that STIP-1 has primarily an intracellu-
lar location, it is intriguing that only one NBD patient's serum sample
yielded an intracellular staining pattern with immunohistochemistry
(Table 1). Also, the commercial STIP-1 antibody used in immunoblot-
ting experiments did not give an appreciable staining with the frozen
rat brain sections despite the fact that human and rat STIP-1 are 100%
identical (data not shown). These results might be explained with the
fact that rat brain STIP-1 expression levels are very low during phys-
iological conditions and below the detection threshold of our immu-
nohistochemistry method and perhaps attain detectable levels only
under stress conditions. Moreover, our immunohistochemistry pro-
cessing techniques might have destroyed the STIP-1 proteins.
Demonstration of antibodies to the neuronal axons and dendritic pro-
cesses in themajority of NBD patients and emergence of these antibodies
during neurological exacerbations suggest that antibody-mediated path-
ogenic mechanismsmight contribute to the development of neurological
symptoms in BD. Whether these antibodies passively develop following
blood–brain barrier breach during the attacks or occur prior to attacks
and are genuinely involved in diseasemechanisms remain to be elucidat-
ed. Presence of neuropil antibodies in BD patients with no neurological
signs and normal MRI ﬁndings supports the latter assumption.
Protein macroarray enables simultaneous screening of thousands
of potential autoantigens regardless of the expression levels of these
antigens in their native host tissues. However, it might fail to deter-
mine the antigenic targets of the antibodies recognizing conforma-
tional epitopes, since the utilized proteins are expressed by bacteria
rather than mammalian cells. Therefore, further investigation of the
targets of the neuropil antibodies by immunoassays that preserve
the conformation of the native proteins is warranted.
BD-associated autoantibody responses directed against diverse
autoantigens have been reported by several investigators (Dinc et al.,
2003; Fresko et al., 2005; Koca et al., 2007; Lee et al., 2009; Vural et
al., 2009), studied by a variety of methods in different BD cohorts (e.g.
BDwith vascular, rheumatological or neurological symptoms). Previous
attempts to look for antibodies in BD have had variable success and the
antibodies identiﬁed were found in only a small fraction of the patients
and were not BD speciﬁc. We also identiﬁed novel autoantibodies that
were only detectable in 5–35% of NBD or BD patients. Since these
were intracellular proteins the antibodies are unlikely to be pathogenicbut their presence supports the notion that BDmight be an autoinﬂam-
matory disorder and speciﬁc antigen-induced immune responses de-
velop against random epitopes expressed by the involved tissues
merely as an epiphenomenon of enhanced inﬂammation (Gül, 2005).
The protein macroarray screening did however identify four novel
antigenic targets. Among these, STIP-1 is a recently discovered HSP
(Zanata et al., 2002; Ji et al., 2007) and thus the identiﬁcation of
STIP-1 antibodies adds a newmember to the list of BD-associated anti-
bodies to stress-induced proteins, such as HSP-60, HSP-65, HSP-70 and
αB-crystallin (Taşçi et al., 1998; Tanaka et al., 1999; Celet et al., 2000;
Birtas-Atesoglu et al., 2008). Although HSP-65 and αB-crystallin anti-
bodies are more prevalent in NBD patients, they might also be detected
in BD patients with no neurological involvement or inMS patients (Gao
et al., 1994; Prabhakar et al., 1994; Vojdani et al., 2003; Yokota et al.,
2010). By contrast, our results suggest that high-titer STIP-1 antibodies
seem to indicate NBD and aremore frequently detected in its parenchy-
mal subtype. However, STIP-1 antibodies have also been determined in
ovarian cancer and rheumatoid arthritis patients (Goëb et al., 2009; Kim
et al., 2010), reducing the speciﬁcity value of this protein as a biomark-
er. Nevertheless, STIP-1 antibodymight still be used as a novel biomark-
er candidate in the differential diagnosis of inﬂammatory CNS disorders,
which closely mimic the symptoms and signs of NBD. Other autoanti-
gens identiﬁed by protein macroarray are not speciﬁc to NBD and
HSP-70 and ING4 antibodies appear to be more prevalent in MS pa-
tients. While the association of HSP-70 antibodies with BD and MS has
long been demonstrated (Birtas-Atesoglu et al., 2008; Yokota et al.,
2010), STMN4 antibodies have only been reported in patients with
pseudoexfoliation glaucoma (Dervan et al., 2010) and, to our knowl-
edge, ING4 antibodies have not been previously described.
Further studies are needed to evaluate whether the autoanti-
bodies or corresponding antigens identiﬁed in our study take part in
the pathogenesis of NBD. In any case, these antibodies could serve
as useful biomarkers to aid in the diagnosis and relapse prediction
of NBD. They might also provide novel therapeutic targets for the spe-
ciﬁc prevention of inﬂammatory CNS disorders.Acknowledgment
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